Centessa Pharmaceuticals plc CNTA

Eli Lilly has announced a definitive agreement to acquire Centessa Pharmaceuticals for $6.3 billion upfront, with potential total value increasing to $7.8 billion through contingent rights. This acquisition follows a notable 5.43% surge in Centessa's stock price, signaling strong market interest in the company's focus on innovative therapies for high unmet medical needs, particularly in sleep disorders. While Centessa has achieved recent funding successes, it remains unprofitable with significant operating losses, highlighting the financial risks associated with this strategic expansion in Lilly's pipeline of neurological treatments.